Loscocco et al. found that the ABCB1 3435TT genotype correlated with a higher probability to achieve an MR3 molecular response in a shorter time in 90 CML patients that were treated with nilotinib [68]. Here, ABCB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.